research A Canadian Consensus on Androgenetic Alopecia: Approach and Management
Experts recommend specific treatments like minoxidil and finasteride for managing hereditary hair loss.
Search
forProducts matching "duta"
Tracking 1 products like 156 Dutas Capsules 0.5mg from by companies like Inhouse Pharmacy. View product »
Sort by
Research
720-750 / 1000+ results 
research Androgenetic Alopecia: What Works?
Topical minoxidil and oral finasteride and dutasteride are the most effective treatments for male and female pattern hair loss, but study quality varies.
research Medical Treatment for Androgenetic Alopecia
New treatments for common hair loss include medications, regenerative therapies, and laser therapy, but may not work for everyone.
research ALOPECIA: AN EXTENSIVE NARRATIVE REVIEW OF TYPES, CAUSES, AND MANAGEMENT STRATEGIES
Effective hair loss treatment requires personalized approaches and patient-provider collaboration.
research Androgenetik Alopesi
The review provided information on various treatments to stop hair thinning and increase hair density in people with common genetic hair loss.
research Dermpath Quiz: Which alopecia does the patient have?
The patient has frontal fibrosing alopecia (FFA).
research B‐ RAF , naevi and melanoma: a complex relationship
Male hair loss is mainly due to thinner hair, not less hair.
research Pharmacotherapy of androgenetic alopecia – a literature review
Combination therapy for hair loss can improve results and reduce side effects.
research Effect of 5-alpha reductase inhibitors in animal models of Parkinson’s disease
5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.
research ADVANCEMENTS IN TREATMENT STRATEGIES FOR ANDROGENETIC ALOPECIA: NOVEL THERAPIES AND FUTURE PERSPECTIVES
New treatments for androgenetic alopecia show promise but need more research for validation.
research May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
Men on 5-alpha-reductase inhibitors might have worse COVID-19 outcomes.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Th,-e mechanistic insights into the application of retinoids and possible adjunct therapeutic treatment to androgenic alopecia
Retinoids may improve hair growth in androgenic alopecia when used with other treatments.
research Dermatological care of gender‐diverse patients in Australia
Australia needs better dermatological guidelines for gender-diverse patients.
research Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment
Plant-based compounds may offer safer prostate cancer treatment with fewer side effects.
research OR09-5 Importance of Islet Intracrinology for Glucose-Stimulated Insulin Secretion (GSIS) in the Male
Androgens and estrogens are crucial for insulin secretion in males.
research Review: Adding α1-blockers to 5α-reductase inhibitors improves lower urinary tract symptoms in men
Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
research Abstract 5561: 20(S)-Protopanaxadiol-aglycone downregulates full-length and ligand-independent splice variants of androgen receptor
20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.
research 200 Uncommon finasteride side effects in male androgenic alopecia
research 199 Hand preference and sexual orientation as useful elements to predict finasteride side effects in male androgenic alopecia
research Karsinoma Nasofaring: Faktor Risiko, Deteksi Dini, Diagnosis, dan Tata Laksana
Nasopharyngeal carcinoma is a common cancer in Indonesia, with risk factors including genetics, diet, and Epstein-Barr virus, and is treated with advanced radiotherapy.
research Re: Clomiphene Citrate and Human Chorionic Gonadotropin are Both Effective in Restoring Testosterone in Hypogonadism: A Short-Course Randomized Study
Clomiphene citrate is a cheap and simple treatment for low testosterone that works as well as human chorionic gonadotropin, alone or combined, especially for men who want to keep their fertility.
research Protocolo terapéutico de la alopecia
Minoxidil and finasteride are the main FDA-approved treatments for hair loss, with other methods showing promise but lacking strong evidence.
research The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention
5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
research A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α-reductase inhibitors GI198745 and finasteride
Both drugs lower DHT levels, with GI198745 being more effective.
research Association of Surgical Risk With Exogenous Hormone Use in Transgender Patients
Hormone treatment for transgender patients may not need to be stopped before surgery, but more research is needed, especially on estrogen.
research Structure of human steroid 5α-reductase 2 with the anti-androgen drug finasteride
Finasteride irreversibly affects human steroid 5α-reductase 2, providing insight into its catalytic mechanism and disease-related mutations.
research Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
Taking 5-α reductase inhibitors for prostate enlargement or hair loss does not significantly raise the risk of erectile dysfunction.
research Long-term use of 5α-reductase inhibitors and the risk of male breast cancer
Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.